fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-07-01
Sanofi-aventis (France)
Juvenile Diabetes Research Foundation (JDRF – USA)
immune therapies, beta cell regeneration / type 1 diabetes R&D
other
See details
2010-07-01 X-Chem (USA)

Roche (Switzerland)
  R&D
See details
2010-06-30 OctoPlus (The Netherlands)
Novartis (Switzerland)
controlled release formulation of an undisclosed compound R&D
other
See details
2010-06-30 TargeGen (USA)

Sanofi-aventis (France)
inhibitor of Janus kinase 2 (JAK-2) and additional tyrosine kinases / hematological cancers, blood disorders other
See details
2010-06-28 Marinomed Biotechnologie (Austria)

Boehringer Ingelheim (Germany)
anti-viral nasal spray based on Marinomed’s anti-viral respiratory technology platform mavirex
licensing
See details
2010-06-25 Metabolex (USA)

Sanofi-Aventis (France)
small molecules that modulate the G-protein coupled receptor 119 (GPR119), including an orally active GPR119 agonist, MBX-2982
/ Type 2 Diabetes
R&D
manufacturing
commercialization/ distribution
development
See details
2010-06-22 Regulus Therapeutics (USA)
Sanofi-Aventis (France)
microRNA therapeutics (micro RNA are small - typically 20 to 25 nucleotides in length- non-coding RNAs that regulate gene expression by interfering with translation or stability of target messenger RNA transcripts)
/ fibrosis
R&D
commercialization/ distribution
See details
2010-06-22 Diamyd Medical (Sweden)
Ortho-McNeil-Janssen Pharmaceuticals (J&J company – USA)
GAD65 antigen-based therapy (Diamyd®) / treatment and prevention of type 1 diabetes and associated conditions
commercialization/ distribution
development
See details
2010-06-17 Drug Safety Executive Council (USA)
Biocortech (France)

  other
See details
2010-06-17 Neurocrine Biosciences (USA)
Boehringer Ingelheim (Germany)
small molecule GPR119 agonists (GPR119 is a G-protein coupled receptor that has been implicated as a novel target for the treatment of Type 2 diabetes. The activation of GPR119 receptors located in the digestive system stimulates incretins, resulting in increased insulin production, while activation of GPR119 receptors located on pancreatic islet beta cells also stimulates insulin secretion).
/ Type 2 diabetes
R&D
See details
2010-06-17 OncoMed Pharmaceuticals (USA)
Bayer Schering Pharma (Germany)
anti-cancer stem cell therapeutics (small molecules, antibody and protein therapeutic products) targeting the Wnt signaling pathway. This pathway is a therapeutic target in halting cancer stem cell activity. / cancer R&D
commercialization/ distribution
development
See details
2010-06-17 Qiagen (Germany) Genome Diagnostics (The Netherlands)

molecular tests targeting the detection of genetic variations in the HLA complex. / prevention and personalized healthcare
commercialization/ distribution
development
See details
2010-06-16 Oncodesign (France),

Janssen Pharmaceutica (Belgium - Johnson&Johnson company
macrocyclic chemistry technology
/ cancer
licensing
See details
2010-06-15 Vivalis (France)
undisclosed animal health company
EB66® cell line licensing
See details
2010-06-15 Talecris Biotherapeutics (USA)
Novartis Vaccines (USA – Switzerland)
post-exposure rabies products / rabies
marketing/ promotion
See details
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]